All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The 1st Annual Meeting of the International Academy for Clinical Hematology (IACH) took place in Paris, France, on September 27–29, 2018. On Friday 28 September, a non-Hodgkin lymphoma session was held, with an abstract presented entitled “Calcineurin and mTOR inhibitor-free GvHD prophylaxis” by Dr. Samer Al-Homsi from NYU Langone Health, New York, NY, USA.
The combination of methotrexate or mycophenolate mofetil (MMF) and a calcineurin or mTOR inhibitor for graft-versus-host disease (GvHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have shown modest clinical activity. Furthermore, these regimens have unfavorable safety profiles, impair immune reconstitution, and weaken graft-versus-tumor (GvT) effect. There is an unmet need to develop new, more efficient strategies for the prophylaxis of GvHD.
Dr. Samer Al-Homsi concluded by stating that calcineurin and mTOR inhibitor-free GvHD prevention seems feasible with a modest toxicity profile. Further trials are underway to confirm these findings.
Subscribe to get the best content related to GvHD delivered to your inbox